Brian O'Callaghan, ObsEva CEO
July 27, 2022 06:55 AM EDTUpdated 07:44 AM
R&D

Ob­sE­va im­plodes on warn­ing that the FDA has set up a road­block for its flag­ship drug

John Carroll

Editor & Founder

Just weeks af­ter scor­ing an ap­proval for its flag­ship drug in Eu­rope, Ob­sE­va has run in­to a reg­u­la­to­ry mael­strom in the US that has evis­cer­at­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

A service from the Financial Times